Search
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA
Albumin human
go.drugbank.com/drugs/DB00062ApprovedInvestigationalAlso known as _Albuminex_ 5% or 25%, one brand of human serum albumin is prepared from the pooled plasma of US donors in FDA-licensed facilities in the US [F229]. … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [L43322] In 2025, the FDA also approved lisocabtagene maraleucel as the first CAR T-cell therapy in the United States for adult patients with relapsed or refractory marginal zone lymphoma (MZL).
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709Approved[L35505] Stratagraft was in the early stages of development as far back as 2009[A237275] and was granted full FDA approval in June 2021.[L35525]
Pancrelipase lipase
go.drugbank.com/drugs/DB13147ApprovedInvestigational[A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35677] It was FDA approved on July 20, 2018.[L3770]
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIn November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements
Zoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigational[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Quinapril
go.drugbank.com/drugs/DB00881ApprovedInvestigational[A184844] Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423]